Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School has taken a thorough look at the newest immunosuppressives and how they work for diabetes patients. His article Nipping Things in the Bud brings to light some of the uses for these medications and why research is ongoing. …
Read More »Evan D. Rosen, M.D., Ph.D
Obesity: How big a problem is it?
Evan David Rosen, M.D., Ph.D. weighs in with his opinion as to how the obestiy numbers got to where they are in his new article Obesity: How big a problem is it? Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School As any casual reader of the …
Read More »A New Face in The Crowd: FGF-21
Although we have a lot of information from ADA Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School, brings us more research he uncovered about a new protein like drug from Lilly. FGF-21 is unique because as an anti-diabetic drug it appears to increase glucose uptake in …
Read More »Some Further Inflammatory Remarks
NF-kB is an inflammation activation protein that seems to work in the liver. What does this have to with diabetes? Everything according to Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School. You can find out why, by reading Some Further Inflammatory Remarks. To an endocrinologist, there …
Read More »Something old, Something new? A new function for a molecule that is already known
Something old, Something new? A new function for a molecule that is already known. Visfatin, a newly discovered hormone for obesity or old hormone with a new story? Find out by reading what Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School, has to say in his …
Read More »Update on Obesity: Partial Answers to Heavy Questions
Dr. Rosen brings us: Update on Obesity: Partial Answers to Heavy Questions When I speak with obese patients in my clinic, I spend a lot of time talking about diet, exercise, and the risks and benefits of drug therapy or surgery. In the end, patients have to decide for themselves …
Read More »Low Testosterone in Type 2 Diabetes; A Hidden Epidemic?
Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School addresses another hidden factor in type 2 diabetes. Low Testosterone; A Hidden Epidemic? Among endocrinologists, it’s well-known that patients with type 1 diabetes are at risk for other hormonal disorders, including hypothyroidism, premature ovarian failure, and Addison’s disease …
Read More »Rethinking the State of the Art for Type 1 Diabetes
A large percentage of human type 1 diabetes is known to be associated with altered forms of the major histocompatibilty complex (MHC), a group of proteins made by immune cells that regulate many of the functions of the immune system. Evan David Rosen, M.D brings us up to date on …
Read More »Update on Resistin
Evan David Rosen, M.D., Ph.D. Assistant Professor of Medicine, Harvard Medical School A few years ago I wrote about an interesting new molecule called resistin. Resistin was isolated independently by three different groups looking for proteins involved in inflammation, fat cell formation, and insulin resistance in mice. For those interested …
Read More »Adult Stem Cells in the Pancreas: Who’s Your Daddy?
Few areas of medical research are as contentious as the study of stem cells. Most folks are aware of the ethical and political debate surrounding the use of embryonic stem cells, with the promise of medical advances balanced against objections to the use of fetal tissue. Evan David Rosen, M.D., …
Read More »